NasdaqGS:ARVN

Stock Analysis Report

Executive Summary

Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Arvinas's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.4%

ARVN

2.0%

US Pharmaceuticals

3.4%

US Market


1 Year Return

6.3%

ARVN

-6.9%

US Pharmaceuticals

5.4%

US Market

Return vs Industry: ARVN exceeded the US Pharmaceuticals industry which returned -6.9% over the past year.

Return vs Market: ARVN matched the US Market which returned 5.4% over the past year.


Shareholder returns

ARVNIndustryMarket
7 Day-5.4%2.0%3.4%
30 Day-33.1%0.5%-1.0%
90 Day-31.6%-1.3%-0.4%
1 Year6.3%6.3%-4.6%-6.9%7.7%5.4%
3 Yearn/a18.5%10.1%46.2%36.8%
5 Yearn/a26.9%13.5%65.6%47.5%

Price Volatility Vs. Market

How volatile is Arvinas's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Arvinas undervalued compared to its fair value and its price relative to the market?

4.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate ARVN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ARVN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ARVN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: ARVN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ARVN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ARVN is overvalued based on its PB Ratio (4.5x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is Arvinas forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-9.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARVN's revenue (6.6% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: ARVN's revenue (6.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if ARVN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Arvinas performed over the past 5 years?

-51.8%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ARVN is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare ARVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARVN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: ARVN has a negative Return on Equity (-52.4%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ARVN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ARVN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Arvinas's financial position?


Financial Position Analysis

Short Term Liabilities: ARVN's short term assets ($163.3M) exceeds its short term liabilities ($20.9M)

Long Term Liabilities: ARVN's short term assets (163.3M) exceeds its long term liabilities (34.6M)


Debt to Equity History and Analysis

Debt Level: ARVN's debt to equity ratio (1.8%) is considered satisfactory

Reducing Debt: Insufficient data to determine if ARVN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: ARVN has a low level of unsold assets or inventory.

Debt Coverage by Assets: ARVN's debt is covered by short term assets (assets are 78.813010x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ARVN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ARVN has sufficient cash runway for 1.723260 years if free cash flow continues to reduce at historical rates of -59.8% each year.


Next Steps

Dividend

What is Arvinas's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ARVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ARVN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ARVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARVN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ARVN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Arvinas's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

John Houston (59yo)

2.1yrs

Tenure

US$6,279,556

Compensation

Dr. John G. Houston, Ph.D. has been President and Chief Executive Officer of Arvinas, Inc. since September 20, 2017. Dr. Houston served as the Chief Scientific Officer and President of Research and Develop ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether John's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.1yrs

Average Tenure

49.5yo

Average Age

Experienced Management: ARVN's management team is considered experienced (2.1 years average tenure).


Board Age and Tenure

2.1yrs

Average Tenure

58yo

Average Age

Experienced Board: ARVN's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$7,927,20002 Jul 19
5AM Venture Management LLC
EntityCompany
Shares360,000
Max PriceUS$22.02
SellUS$9,787,50002 Jul 19
5AM Venture Management LLC
EntityCompany
Shares450,000
Max PriceUS$21.75
SellUS$3,733,50011 Jun 19
5AM Venture Management LLC
EntityCompany
Shares190,000
Max PriceUS$19.65
BuyUS$14,66002 Apr 19
Ian Taylor
EntityIndividual
Role
Chief Scientific Officer
Chief Scientific Officer
Shares1,000
Max PriceUS$14.66
SellUS$5,112,68401 Apr 19
5AM Venture Management LLC
EntityCompany
Shares361,129
Max PriceUS$14.16
BuyUS$51,41001 Apr 19
Timothy Shannon
EntityIndividual
Role
Chairman of the Board
Chairman of The Board
Shares3,500
Max PriceUS$14.69

Ownership Breakdown


Management Team

  • Craig Crews

    Founder

    • Tenure: 0yrs
  • Sean Cassidy (49yo)

    CFO & Treasurer

    • Tenure: 6.3yrs
    • Compensation: US$2.80m
  • Ron Peck

    Chief Medical Officer

    • Tenure: 0.3yrs
  • Rob Kleinfield

    Chief Development Officer

    • Tenure: 4.1yrs
  • John Houston (59yo)

    CEO, President & Director

    • Tenure: 2.1yrs
    • Compensation: US$6.28m
  • Ian Taylor (56yo)

    Chief Scientific Officer

    • Tenure: 0.6yrs
    • Compensation: US$1.99m
  • Matthew Batters (43yo)

    Vice President of Business Development & Counsel

    • Tenure: 0yrs
  • Steve Weiss (50yo)

    Vice President of Human Resources

    • Tenure: 0yrs
  • Randy Teel (40yo)

    Vice President of Corporate Development

    • Tenure: 1.4yrs

Board Members

  • Brad Margus (58yo)

    Director

    • Tenure: 5.9yrs
    • Compensation: US$292.25k
  • Tim Shannon (60yo)

    Chairman of The Board

    • Tenure: 6.3yrs
    • Compensation: US$19.58k
  • Ted Kennedy (58yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$507.88k
  • Craig Crews

    Founder

    • Tenure: 0yrs
  • Leslie Norwalk (54yo)

    Director

    • Tenure: 0.3yrs
  • Briggs Morrison (59yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$571.95k
  • Liam Ratcliffe (56yo)

    Director

    • Tenure: 4yrs
    • Compensation: US$10.44k
  • Kush Parmar (38yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$11.10k
  • John Houston (59yo)

    CEO, President & Director

    • Tenure: 2.1yrs
    • Compensation: US$6.28m
  • Jakob Loven (41yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$11.10k

Company Information

Arvinas, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arvinas, Inc.
  • Ticker: ARVN
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$564.382m
  • Shares outstanding: 33.69m
  • Website: https://www.arvinas.com

Number of Employees


Location

  • Arvinas, Inc.
  • 5 Science Park
  • 395 Winchester Avenue
  • New Haven
  • Connecticut
  • 6511
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARVNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2018

Biography

Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company’s lead products include ARV-110, prote ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:45
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.